At the news
? MIXEDIMPACT 6/10 8-K filed Mar 5, 2026 at 06:36 ET
Kura Oncology reported its first commercial revenue of $2.1 million from KOMZIFTI, its newly approved AML drug, in Q4 2025. Despite this milestone, the company reported a significant net loss increase to $81 million due to higher R&D and commercialization expenses. The company maintains a strong cash position of $667.2 million and anticipates $180 million in collaboration payments.
- Generated $2.1 million in net product revenue from KOMZIFTI in Q4 2025 (first five weeks of sales)
- Net loss increased to $81 million in Q4 2025 from $19.2 million in Q4 2024
- Cash position of $667.2 million as of December 31, 2025
- Anticipates $180 million in collaboration payments from Kyowa Kirin
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access